Drug Trial Radar · NCT02924766
A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
Last checked: Nov 19, 2026Latest source record: Jul 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Oct 3, 2016
Primary completion
Jul 18, 2019
Study completion Jul 19, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult men with metastatic castration resistant prostate cancer (mCRPC) who may or may not have deoxyribonucleic acid (DNA)-repair anomalies.
Conditions
- Prostatic Neoplasms
Interventions
NiraparibDrug
Participants will start with niraparib 200 mg once daily.
ApalutamideDrug
Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
Abiraterone AcetateDrug
Participants will receive 1000 mg (4\*250mg) once daily.
PrednisoneDrug
Participants will receive 10 mg (1\*5 mg twice daily).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine Recommended Phase 2 dose (RP2D) of Niraparib in Combination With 240 milligram (mg) Apalutamide or 1,000 mg Abiraterone Acetate Plus 10 mg Prednisone (5 mg Twice Daily) in Part 1Time frame: Up to 56 days
- Number of Participants With Incidence and Severity of Adverse Events (Part 2)Time frame: Up to 30 days after last dose
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
West Hollywood, California
Site not named
Louisville, Kentucky
Site not named
Portland, Oregon
Site not named
Myrtle Beach, South Carolina
Site not named
Vancouver, British Columbia, Canada
Site not named
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.